PTC Therapeutics, Inc. (PTCT): Price and Financial Metrics
PTCT Price/Volume Stats
| Current price | $33.01 | 52-week high | $59.84 |
| Prev. close | $33.62 | 52-week low | $17.53 |
| Day low | $32.81 | Volume | 992,500 |
| Day high | $34.83 | Avg. volume | 988,115 |
| 50-day MA | $28.80 | Dividend yield | N/A |
| 200-day MA | $28.53 | Market Cap | 2.53B |
PTCT Stock Price Chart Interactive Chart >
PTC Therapeutics, Inc. (PTCT) Company Bio
PTC Therapeutics is a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. The company was founded in 1998 and is based in South Plainfield, New Jersey.
Latest PTCT News From Around the Web
Below are the latest news stories about PTC THERAPEUTICS INC that investors may wish to consider to help them evaluate PTCT as an investment opportunity.
Biogen's (BIIB) Rare Disease Drug Skyclarys Gets CHMP Nod in EUBiogen (BIIB) gets positive CHMP opinion recommending marketing authorization to Skyclarys in the EU for the treatment of Friedreich's ataxia in patients aged 16 years and older. |
Insider Buying: CFO Pierre Gravier Acquires 7,700 Shares of PTC Therapeutics Inc (PTCT)In the realm of stock market movements, insider trading activity is often a significant indicator that can provide insights into a company's potential future performance. |
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 10, 2023, the company approved non-statutory stock options to purchase an aggregate of 3,575 shares of its common stock and 3,035 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to two new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation. |
Solid Biosciences' (SLDB) DMD Drug Gets Fast Track Tag, Stock UpSolid Biosciences (SLDB) gains 68% as the FDA grants Fast Track designation to the company's gene therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy. |
PTC Therapeutics Provides Updates on Translarna™ Regulatory ActivitiesPTC Therapeutics, Inc. (NASDAQ: PTCT) announced today an update on Translarna™ (ataluren) regulatory activities in Europe and the United States. |
PTCT Price Returns
| 1-mo | 22.17% |
| 3-mo | 31.67% |
| 6-mo | 62.93% |
| 1-year | -40.86% |
| 3-year | -18.15% |
| 5-year | -7.97% |
| YTD | 19.78% |
| 2023 | -27.80% |
| 2022 | -4.17% |
| 2021 | -34.74% |
| 2020 | 27.07% |
| 2019 | 39.95% |
Continue Researching PTCT
Want to do more research on Ptc Therapeutics Inc's stock and its price? Try the links below:Ptc Therapeutics Inc (PTCT) Stock Price | Nasdaq
Ptc Therapeutics Inc (PTCT) Stock Quote, History and News - Yahoo Finance
Ptc Therapeutics Inc (PTCT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...